Our mission is to develop disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases to address the unmet medical need.
-
Highlight
Watch Herantis Pharma’s Full Year 2023 webcast here
-
Highlight
Herantis Pharma announces positive topline data from the Phase 1a clinical trial of HER-096
Latest news and releases
-
Herantis Pharma publishes 2H and FY 2023 report today.
Read more » -
Herantis Pharma: HER-096 promotes functional recovery and regeneration of stressed neurons – two poster presentations at AD/PD 2024 conference.
Read more » -
Herantis Pharma: Invitation to Full Year 2023 results webcast on March 6, 2024
Read more » -
Herantis Pharma participating at 19th Annual Biomarkers Congress and at the Biotechgate Digital Partnering event.
Read more » -
Herantis Pharma Oyj: Managers’ Transactions – Tone Kvåle
Read more » -
Proposals of the Shareholders’ Nomination Committee to Herantis Pharma Plc’s Annual General Meeting 2024
Read more »